Article

B+L Stellaris receives 510(k) clearance

The FDA has granted 510(k) clearance to Bausch + Lomb’s comprehensive surgical platform-the Stellaris PC Vision Enhancement System-for the integrated 523-nm laser and software.

 

Bridgewater, NJ-The FDA has granted 510(k) clearance to Bausch + Lomb’s comprehensive surgical platform-the Stellaris PC Vision Enhancement System-for the integrated 523-nm laser and software.

“This updated technology is another demonstration of Bausch + Lomb’s unwavering commitment to continuous innovation and improvement that is inspired by the evolving needs of our customers and the patients they serve,” said Cal Roberts, MD, chief medical officer, Bausch + Lomb.

With the advance, the surgical platform now offers the following to surgeons’ facilities:

·      A fully integrated 532-nm green laser, which is upgradable for the existing surgical platform and connects within the sterile field.

·      A wireless, dual linear foot pedal that features integrated laser control and improved design offering versatility and flexibility for procedural needs. The pedal and ergonomic footrest aims to improve comfort for longer procedures by reducing pitch.  An optional LIO foot pedal, cable, and headset are also available.

·      A full portfolio of multifunction laser fibers that meet a wide range of procedural needs, including straight, curved, illuminated, and aspirating probes with a soft tip for added security when working close to the retina.

·      A redesigned interface and laser control software that offers improved clarity, enhanced contrast, and ease of use for both surgeons and staff.

 

 

“To address the clinical, efficiency, and value requirements of the ophthalmic surgeon, the (surgical platform) now offers even greater procedural choice and more opportunities to improve surgical outcomes, from the lens to the retina, on a single, integrated fully capable system,” added Dr. Roberts.

 

For more articles in this issue of Ophthalmology Times eReport, click here.

 

 

To receive weekly clinical news and updates in ophthalmology, subscribe to the Ophthalmology Times eReport.

Newsletter

Don’t miss out—get Ophthalmology Times updates on the latest clinical advancements and expert interviews, straight to your inbox.

Related Videos
(Image credit: Ophthalmology Times)  ASCRS 2025: Joaquin De Rojas, MD, leverages machine learning model to predict arcuate outcomes
(Image credit: Ophthalmology Times) ASCRS 2025: AnnMarie Hipsley, DPT, PhD, presents VESA for biomechanical simulation of presbyopia progression
Shehzad Batliwala, DO, aka Dr. Shehz, discussed humanitarian ophthalmology and performing refractive surgery in low-resource, high-risk areas at the ASCRS Foundation Symposium.
(Image credit: Ophthalmology Times) ASCRS 2025: Advancing vitreous care with Inder Paul Singh, MD
(Image credit: Ophthalmology Times) The Residency Report: Study provides new insights into USH2A target end points
Lisa Nijm, MD, says preoperative osmolarity testing can manage patient expectations and improve surgical results at the 2025 ASCRS annual meeting
At the 2025 ASCRS Annual Meeting, Weijie Violet Lin, MD, ABO, shares highlights from a 5-year review of cross-linking complications
Maanasa Indaram, MD, is the medical director of the pediatric ophthalmology and adult strabismus division at University of California San Francisco, and spoke about corneal crosslinking (CXL) at the 2025 ASCRS annual meeting
(Image credit: Ophthalmology Times) ASCRS 2025: Taylor Strange, DO, assesses early visual outcomes with femto-created arcuate incisions in premium IOL cases
(Image credit: Ophthalmology Times) ASCRS 2025: Neda Shamie, MD, shares her early clinical experience with the Unity VCS system
© 2025 MJH Life Sciences

All rights reserved.